Combination targeted therapy provides durable remission for patients with CLL

(University of Texas M. D. Anderson Cancer Center) A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL), according to researchers at The University of Texas MD Anderson Cancer Center. Findings from the single-institution Phase II study were published today in JAMA Oncology and provide the longest follow-up data on patients treated with this drug regimen.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news